On November 16, the US Food and Drug Administration (FDA) approved capivasertib in combination with fulvestrant for adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with 1 or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least 1 endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.
For more information read the FDA announcement and the AstraZeneca announcement.
Posted 11/17/2023
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
